New treatment options provide hope and possibilities for people living with migraine. Better prevention can mean fewer debilitating attacks and more non-headache days for work and family. But clinical guidelines do not keep pace with this scientific progress and can limit who can benefit.
On August 31, 2026, the American Academy of Neurology and the American Headache Society published updated guidelines on migraine prevention and treatment in adults. The recommendations were last updated over a decade ago in 2012, and the new guidance reflects medical progress developed over the intervening years.
One particularly significant advancement in treatment of migraine is those that target calcitonin gene-related peptides, or CGRP, which have high potential for reducing migraine days for many individuals by reducing swelling and inflammation in the brain. Alongside established treatments like beta-blockers and antiseizure medications, increasing evidence suggests CGRP-targeted medications could prevent migraine in adults currently experiencing four or more moderate-to-severe headache days per month.
For clinicians, the updated guidelines provide a broader base of evidence and more choices, increasing the chance of finding the right treatment for each patient. People living with migraine experience varying degrees of headache frequency and severity, and react differently to medications. More options mean a better chance that effective, well-tolerated treatment will be made available for every patient.
Keeping Recommendations Current
Even a recent update is a static snapshot that cannot include all relevant research. Therefore, this most recent guideline update does not reflect all the current evidence that supports all available treatment options for patients. By the time evidence is thoroughly reviewed and updated recommendations are published, additional new evidence has and will continue to emerge in this swiftly moving field of study, especially if guidelines are only updated every decade. Sometimes treatments are left out of guidelines because they were not available by the cutoff date.
When Guidelines Lag Behind
Because clinical guidelines influence prescribing and insurance coverage decisions, recommendations that lag behind the available evidence create roadblocks to patients receiving the best care.
More frequent updates to guidelines, as well as the supporting consensus statements that are published by the American Headache Society, should help ensure patients and prescribers receive the best available information about all treatment and prevention options.
Including Patient Voices in Guideline Development
While the updated guidelines represent meaningful progress toward better migraine care, the development process has room for improvement. Not only would more frequent updates improve care, but experts would like headache specialists and people living with migraine disease to be included in the guideline development process. Because clinical expertise and patient experience help identify practical barriers and overlooked results, adding their voices alongside clinical trial data would result in more well-rounded guidance.
Timely guidance can help turn medical innovation into real-world symptom improvement. If better guidance results in wider access, a wealth of new treatments will now be more available to patients who need them.
